Document Detail

Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study.
MedLine Citation:
PMID:  15172775     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Recombinant human erythropoietin is the standard treatment for anaemia related to chronic kidney disease, and its widespread use has been favoured by a very high therapeutic index. However, since 1998, more than 200 patients worldwide with chronic kidney disease treated in this way have developed neutralising antibodies to erythropoietin, causing pure red cell aplasia. We aimed to collate clinical and pathological features in patients unequivocally shown to have erythropoietin-induced pure red cell aplasia. METHODS: We retrospectively obtained data from the files of 47 patients with pure red cell aplasia. We assessed treatment and outcome of patients and defined recovery from pure red cell aplasia as an increase in reticulocyte counts to more than 20 000 per microL in patients who were no longer transfusion-dependent. FINDINGS: When patients developed pure red cell aplasia, all were receiving erythropoietin subcutaneously, and the product most typically prescribed was epoetin alfa (Eprex, Ortho Biotech). The median delay between start of erythropoietin treatment and occurrence of pure red cell aplasia was 11 months (IQR 7.5-14). Nine patients received no immunosuppressive treatment, and none of these recovered. Of 37 patients who received immunosuppressive therapy, 29 (78%) recovered. All six patients who received a kidney transplant recovered within 1 month, and recovery rates were between 56% and 88% in patients treated with corticosteroids, corticosteroids plus cyclophosphamide, or ciclosporin. No relapse of pure red cell aplasia happened after stopping immunosuppressive treatment, but no patient was rechallenged with erythropoietin. INTERPRETATION: Immunosuppressive treatment accelerates recovery from erythropoietin-induced pure red cell aplasia.
David Verhelst; Jérôme Rossert; Nicole Casadevall; Anne Krüger; Kai-Uwe Eckardt; Iain C Macdougall
Related Documents :
11465435 - Autologous blood transfusion in oral and maxillofacial surgery patients with the use of...
20154545 - Predicting change of hemoglobin after transfusion in hemodynamically stable anemic pati...
9371095 - Plasmodium falciparum: evaluation of lactate dehydrogenase in monitoring therapeutic re...
7629585 - Penile scintigraphy for priapism in sickle cell disease.
16379035 - Serum igf-1 in treated acromegaly - how normal is "normal"?
20434205 - Clinical, biological, and molecular characteristics of clonal mast cell disorders prese...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Lancet     Volume:  363     ISSN:  1474-547X     ISO Abbreviation:  Lancet     Publication Date:  2004 May 
Date Detail:
Created Date:  2004-06-02     Completed Date:  2004-06-15     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  England    
Other Details:
Languages:  eng     Pagination:  1768-71     Citation Subset:  AIM; IM    
Department of Nephrology, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, and Pierre and Marie Curie University, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenal Cortex Hormones / therapeutic use
Anemia / drug therapy,  etiology
Erythropoietin, Recombinant / adverse effects*
Immunoglobulins, Intravenous / therapeutic use
Immunosuppressive Agents / therapeutic use
Kidney Failure, Chronic / complications
Middle Aged
Red-Cell Aplasia, Pure / chemically induced*,  therapy*
Retrospective Studies
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Erythropoietin, Recombinant; 0/Immunoglobulins, Intravenous; 0/Immunosuppressive Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.
Next Document:  Parent-of-origin effect in multiple sclerosis: observations in half-siblings.